Get started
Work

Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib

Year: 2022
Type: conference-abstract
DOI: 10.1158/1538-7445.sabcs21-pd2-03
Authors: Jamie O Brett, Taronish D Dubash, Andrzej Niemierko, Veronica Mariotti, Leslie SL Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Maxwell R Lloyd, Laura M Spring, Douglas Micalizzi, Maristela Onozato, Dante Che, Adam Brufsky, Kevin M Kalinsky, Cynthia X Ma, Joyce O’Shaughnessy, Hyo S Han, A. John Iafrate, Shyamala Maheswaran, Daniel A Haber, Aditya Bardia, Seth A Wander
Institutions: Massachusetts General Hospital, Moffitt Cancer Center, Baylor University Medical Center, Washington University in St. Louis, University of Pittsburgh Medical Center, UPMC Hillman Cancer Center, Beth Israel Deaconess Medical Center, Emory University, Winship Cancer Institute
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W4221122652
Cites:
Cited by: 1
Related to: 10